Alpha 2.0
Login Register
» Authors » Timothy R Donahue

Timothy R Donahue

Explore the profile of Timothy R Donahue including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 113
Citations 3389
Followers 0
Related Specialties
General Surgery
Gastroenterology
Oncology
Top 10 Co-Authors
David W Dawson
Howard A Reber
O Joe Hines
Nanping Wu
Luyi Li
Caius G Radu
V Raman Muthusamy
Evan R Abt
Mark D Girgis
James S Tomlinson
Published In
JAMA Surg
Pancreas
Surgery
J Gastrointest Surg
Mol Cancer Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
Perspectives, Experiences, and Opportunities of Academic Surgeons in the Era of Healthcare Corporatization
Sakowitz S, Bakhtiyar S, Sienna N, Mallick S, Ali K, Benharash P, et al.
Ann Surg . 2025 Jan; PMID: 39811961
Objective: To characterize contemporary surgeons' viewpoints and perspectives on the academic mission during healthcare corporatization. Summary Background Data: Academic surgery, traditionally driven by the tripartite missions of excellence in clinical...
2.
Oldest Reported Case of Solid Pseudopapillary Neoplasm: Diagnostic Challenge and Surgical Management
Bachu V, Bahdi F, Makker J, Donahue T, Kim S
Dig Dis Sci . 2025 Jan; PMID: 39806084
No abstract available.
3.
ASO Visual Abstract: Larger Tumor Size and Elevated Serum Chromogranin A Levels Predict Metastatic Disease on DOTATATE Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Labora A, Shimizu T, Moore A, Premji A, Armstrong W, Chen K, et al.
Ann Surg Oncol . 2024 Nov; 32(2):1197-1198. PMID: 39557724
No abstract available.
4.
Ampullary Adenocarcinoma-Advancing Prognostication and Personalized Treatment
Zheng S, Donahue T
JAMA Surg . 2024 Sep; 159(12):1374. PMID: 39259552
No abstract available.
5.
Oncogenic pathway signatures predict the risk of progression and recurrence in well-differentiated pancreatic neuroendocrine tumors
Mederos M, Court C, Dipardo B, Pisegna J, Dawson D, Hines O, et al.
J Surg Oncol . 2024 Aug; 130(5):1070-1077. PMID: 39155697
Background: Pancreatic neuroendocrine tumors (pNETs) are genomically diverse tumors. The management of newly diagnosed well-differentiated pNETs is limited by a lack of sensitivity of existing biomarkers for prognostication. Our goal...
6.
Center-level variation in hospitalization costs of pancreaticoduodenectomy for pancreatic cancer
Le N, Chervu N, Ng A, Gao Z, Cho N, Charland N, et al.
Surgery . 2024 Jul; 176(3):866-872. PMID: 38971697
Background: Pancreaticoduodenectomy is a highly morbid operation with significant resource utilization. Using a national cohort, we examined the interhospital variation in pancreaticoduodenectomy hospitalization cost in the United States. Methods: Adults...
7.
Empowering Leaders. Better Together
Donahue T
Surgery . 2024 Jul; 176(3):757-762. PMID: 38965006
No abstract available.
8.
Expression of Concern: Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Hong A, Piva M, Liu S, Hugo W, Lomeli S, Zoete V, et al.
Cancer Discov . 2024 Jul; 14(7):1357. PMID: 38946326
No abstract available.
9.
Larger Tumor Size and Elevated Serum Chromogranin A Levels Predict Metastatic Disease on DOTATATE Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Labora A, Shimizu T, Moore A, Premji A, Armstrong W, Chen K, et al.
Ann Surg Oncol . 2024 Jun; 31(10):6875-6882. PMID: 38909116
Purpose: DOTATATE PET/CT (DOTATATE) is superior to conventional imaging in detecting metastasis for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, limited availability, high-cost, and additive radiation exposure necessitate guidelines for its use....
10.
The impact of the California state lockdown during the COVID-19 pandemic on management of patients with pancreatic ductal adenocarcinoma
Oviedo P, Burns S, Chen W, Mandl H, Rosso C, Radgoudarzi N, et al.
J Surg Oncol . 2024 Jun; 130(2):276-283. PMID: 38894577
Background And Objectives: The SARS-COVID-19 pandemic significantly limited healthcare access. We sought to evaluate whether California's lockdown in March 2020 affected staging and time to treatment of pancreatic ductal adenocarcinoma...